Outcome for key efficacy end points at 104 weeks based on week 24 results Therapeutic PCR-negative HBeAg ALT Virological response HBV DNA seroconversion normalisation breakthrough* n/ N (%) n/ N (%) n/ N (%) n/ N (%) n/ N (%)